14 research outputs found
α‑Glucosidase Inhibitory Hydrolyzable Tannins from <i>Eugenia jambolana</i> Seeds
Three new hydrolyzable tannins including two gallotannins,
jamutannins A (<b>1</b>) and B (<b>2</b>), and an ellagitannin,
iso-oenothein C (<b>3</b>), along with eight known phenolic
compounds were isolated from the seeds of <i>Eugenia jambolana</i> fruit. The structures were elucidated on the basis of spectroscopic
data analysis. All compounds isolated were evaluated for α-glucosidase
inhibitory effects compared to the clinical drug acarbose
Jiangrines A–F and Jiangolide from an Actinobacterium, <i>Jiangella gansuensis</i>
Seven new compounds, including five
pyrrol-2-aldehyde derivatives,
jiangrines A–E (<b>1</b>–<b>5</b>), one
indolizine derivative, jiangrine F (<b>7</b>), and one glycolipid,
jiangolide (<b>8</b>), along with a known compound, pyrrolezanthine
(<b>6</b>), were isolated from the fermentation broth of <i>Jiangella gansuensis</i>, an actinobacterium assigned to a novel
family, Jiangellaceae, and a novel order, Jiangellales. The structures
were elucidated by detailed spectroscopic analysis and through chemical
methods. Compounds <b>1</b>, <b>2</b>, <b>3</b>/<b>4</b>, <b>5</b>, <b>6</b>, and <b>8</b> demonstrated
inhibitory effects on lipopolysaccharide-induced NO production in
RAW 264.7 macrophage cells, with IC<sub>50</sub> values of 97.8, 60.7,
30.1, 54.9, 58.8, and 61.4 μM, respectively
Phloroglucinol Derivatives with Protein Tyrosine Phosphatase 1B Inhibitory Activities from <i>Eugenia jambolana</i> Seeds
Fifteen new phloroglucinol derivatives,
jamunones A–O (<b>1–8</b> and <b>10–16</b>, respectively), along
with one known analogue spiralisone C (<b>9</b>), were isolated
from <i>Eugenia jambolana</i> seeds. Their structures were
elucidated by detailed nuclear magnetic resonance and mass spectrometry
spectroscopic data interpretation. Compounds <b>1–9</b>, <b>11</b>, <b>12</b>, and <b>14–16</b> inhibited protein tyrosine phosphatase 1B activity with IC<sub>50</sub> values ranging from 0.42 to 3.2 μM
Rates of the Mp1p-positive case in different CD4<sup>+</sup> count level.
Rates of the Mp1p-positive case in different CD4+ count level.</p
Baseline Characteristics of 784 Participants Undergoing Mp1p Antigen Screening Stratified by Mp1p Antigen Status.
Baseline Characteristics of 784 Participants Undergoing Mp1p Antigen Screening Stratified by Mp1p Antigen Status.</p
Data of the research.
BackgroundTalaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis.Methodology/Principal findingsWe performed a cross-sectional study of HIV-infected antiretroviral therapy (ART)-naïve adult patients who were seen in 2018 at Guangzhou Eighth People’s Hospital, Guangzhou Medical University. Serum samples collected from all the 784 enrolled patients were tested for Mp1p antigen using double-antibody sandwich enzyme-linked immunosorbent assay. A culture of pathogen was conducted in 350 clinically suspected patients to confirm talaromycosis. The overall prevalence of talaromycosis based on the Mp1p antigen detection was 11.4% (89/784) and peaked at 32.2% (75/233) in patients with CD4+ ≤50 Nr/μl. Logistic regression analysis found Mp1p antigen positive rate decreased with the increase in CD4+ counts (OR 0.982, 95% CI 0.977–0.987, P+ count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a Talaromyces marneffei, 75/350 (21.4%) patients were Mp1p antigen positive. The Mp1p antigen assay showed a good agreement to the culture of pathogen, and the sensitivity, specificity, positive predictive value, negative predictive value and kappa value was 71.6% (68/95), 97.3% (248/255), 90.7% (68/75), 90.2% (248/275), and 0.737, respectively. The screening accuracy of the Mp1p antigen assay in patients with CD4+ counts of ≤50 Nr/μl was superior to that in those with higher CD4+ counts.Conclusions/SignificanceMp1p antigen screening can be an effective tool for more efficient diagnosis of Talaromycosis, especially in HIV/AIDS patients with low CD4+ counts. Future validation studies are needed.</div
Rates of the Mp1p-positive case in different CD4<sup>+</sup> count level among patients received specimen culture and/or histopathological examination.
Rates of the Mp1p-positive case in different CD4+ count level among patients received specimen culture and/or histopathological examination.</p
Cut-point analysis using Youden’s J Index.
BackgroundTalaromycosis is one of the most common opportunistic infections in human immunodeficiency virus (HIV) infected patients. However, few researches have explored the prevalence in Southern China and fully assessed the value of the Mp1p antigen screening for the diagnosis of talaromycosis.Methodology/Principal findingsWe performed a cross-sectional study of HIV-infected antiretroviral therapy (ART)-naïve adult patients who were seen in 2018 at Guangzhou Eighth People’s Hospital, Guangzhou Medical University. Serum samples collected from all the 784 enrolled patients were tested for Mp1p antigen using double-antibody sandwich enzyme-linked immunosorbent assay. A culture of pathogen was conducted in 350 clinically suspected patients to confirm talaromycosis. The overall prevalence of talaromycosis based on the Mp1p antigen detection was 11.4% (89/784) and peaked at 32.2% (75/233) in patients with CD4+ ≤50 Nr/μl. Logistic regression analysis found Mp1p antigen positive rate decreased with the increase in CD4+ counts (OR 0.982, 95% CI 0.977–0.987, P+ count was 50 Nr/μl or less. Among the 350 patients received both fungal culture and Mp1p antigen detection, 95/350 (27.1%) patients were culture-positive for a Talaromyces marneffei, 75/350 (21.4%) patients were Mp1p antigen positive. The Mp1p antigen assay showed a good agreement to the culture of pathogen, and the sensitivity, specificity, positive predictive value, negative predictive value and kappa value was 71.6% (68/95), 97.3% (248/255), 90.7% (68/75), 90.2% (248/275), and 0.737, respectively. The screening accuracy of the Mp1p antigen assay in patients with CD4+ counts of ≤50 Nr/μl was superior to that in those with higher CD4+ counts.Conclusions/SignificanceMp1p antigen screening can be an effective tool for more efficient diagnosis of Talaromycosis, especially in HIV/AIDS patients with low CD4+ counts. Future validation studies are needed.</div
Flow chart of the study.
PPV: positive predictive value, NPV: negative predictive value, Kappa: Cohen’s kappa coefficient.</p
Screening efficacy of Mp1p antigen in the various CD4<sup>+</sup> count levels.
Screening efficacy of Mp1p antigen in the various CD4+ count levels.</p